COVID-19 and Clinical Trials: a CRO's…
OCT to Remain Fully Operational, Available…
OCT Clinical provides multiple services in an ophthalmology study, now ongoing in five Eastern European countries.
ST. PETERSBURG, RUSSIA — March 6th, 2020. OCT Clinical, a leading European CRO headquartered in Russia, today announced it will conduct an ophthalmology study in collaboration with a Europe-based biopharmaceutical company.
The multicenter, randomized, double-blind, investigator-masked, placebo-controlled phase III study will run in two parallel groups. The primary goal is to evaluate the efficacy of the study medicine against that of the active competitor. The recruitment target for the study is 400 male and female patients aged 18 to 65 with glaucoma or ocular hypertension.
“We are happy to provide our input with additional countries in order to assure that study enrollment is strictly completed within planned timelines,” said Gatis Klaucans, Senior Project Manager and Head of OCT Clinical’s Office in Latvia. “We are enjoying the challenge and useful experience that we are gaining while working on the same project in five very different countries, which are in different phases of the study.”
Within this project OCT Clinical is responsible for running the study in Bulgaria, Latvia, Georgia, Ukraine and Russia, and is now actively enrolling patients. In addition to enrollment, OCT Clinical is responsible for a wide scope of services including site management, monitoring, regulatory, drug import and logistics in the five Eastern European countries.